Tezacaftor, also known asVX-661, is CFTR modulator. VX-661 is potentially useful for treatment of cystic fibrosis disease. Cystic fibrosis (CF) is a genetic disease caused by defects in the CF transmembrane regulator (CFTR) gene, which encodes an epithelial chloride channel. The most common mutation, Δ508CFTR, produces a protein that is misfolded and does not reach the cell membrane. VX-661 can correct trafficking of Δ508CFTR and partially restore chloride channel activity.
Dhamankar, Varsha; Dinehart, Kirk Raymond; Dokou, Eleni; Ferris, Lori Ann; Gopinathan, Nishanth; McCarty, Katie; Metzler, Catherine; Zhang, Beili. Preparation of cystalline forms and pharmaceutical compositions comprising them as CFTR modulators for the treatment of cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019079760. (2019).
Haseltine, Eric L.; Moskowitz, Samuel; Robertson, Sarah; Waltz, David. Methods of treatment for cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2019018395. (2019).
Hadida-Ruah, Sara Sabina; Grootenhuis, Peter Diederik Jan; Van Goor, Fredrick F.; Zhou, Jinglan; Bear, Brian Richard; Miller, Mark Thomas; McCartney, Jason; Numa, Mehdi Michel Djamel; Yang, Xiaoqing; Nair, Nitin. Preparation of acylaminoindole compounds as modulators of ATP-binding cassette transporters. Assignee Vertex Pharmaceuticals Incorporated, USA. US 20160271105. (2016).
Zhang, Chengzhi; Chakma, Justin. Preparation of cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator. Assignee Auspex Pharmaceuticals, Inc., USA. WO 2016109362. (2016).
Phenix, Brian Dean; Bagnol, Laurent Jean-Claude; Brodeur, Geoffrey Glen; Chandran, Sachin; Dokou, Eleni; Ferris, Lori Ann; Knezic, Dragutin; McCarty, Katie Lynn; Medek, Ales; Waggener, Sara A. Method for preparation of quinolinone carboxamides, indole carboxamides and pharmaceutical compositions containing them for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2015160787. (2015).
Alargova, Rossitza Gueorguieva; Dunbar, Craig Antony; Kadiyala, Irina Nikolaevna. Oral compositions of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide for treatment of cystic fibrosis. Assignee Vertex Pharmaceuticals Incorporated, USA. WO 2014014841. (2014).
